Anavex Life Sciences Corp (AVXL)

[indialong]

This is unlikely to happen until the trials are over and the results are unblinded. Unlike the Alzheimers 2A (which was unblinded and had no placebo group), the current trials are designed so that no one can know which arm they have been assigned to (i.e., treatment or placebo). So even if a particular trial subject may appear to be improving in some way, there is no way it can accurately be attributed to 2-73 because there is no way to know if that subject is receiving 2-73 until the trial is over. Maybe the subject who is improving, or their caregiver, may suspect they are receiving 2-73 because of the improvement, but no journalist with integrity would be able to report on it without disclosing that there is no way to know whether it has anything to do with the drug.


PDD https://clinicaltrials.gov/ct2/show/NCT03774459?term=anavex&rank=2

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)



Rett https://clinicaltrials.gov/ct2/show/NCT03758924?term=anavex&rank=3

Masking: Triple (Participant, Care Provider, Investigator)



Alzheimers 2B/3 https://clinicaltrials.gov/ct2/show/NCT03790709?term=anavex&rank=4

Intervention Model Description: Randomized 1:1:1 to two different ANAVEX2-73 doses or placebo
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)